tender_id,publication_date,issuing_authority_name,issuing_authority_type,issuing_authority_website,issuing_authority_phone,issuing_authority_fax,issuing_authority_email,tender_title,estimated_contract_value,cpv_classification,contract_duration,winning_company,winning_company_nif,final_contract_value,motivation,contract_value_raw_EUR
51/F/24/SU/GE/D/0302-1,21-10-2024,Address Management University Hospital of Gran Canaria Doctor Negrín,Regional authority,http://www.gobiernodecanarias.org/sanidad/scs,+034 928450147,+034 928449814,ucahugcdn.scs@gobiernodecanarias.org,"Supply of the active ingredients adalimumab, rituximab and trastuzumab","150.457,5 EUR.",33690000,Del 01/02/2023,Sandoz Farmaceutica,A08233801,"150.457,5 EUR",According to the Pharmacy Service Report,150457.5
51/F/24/SU/GE/D/0305,29-10-2024,Address Management University Hospital of Gran Canaria Doctor Negrín,Regional authority,http://www.gobiernodecanarias.org/sanidad/scs,+034 928450147,+034 928449814,ucahugcdn.scs@gobiernodecanarias.org,"Contract based on the framework agreement for the supply of the active ingredients ADALIMUMAB, RITUXIMAB and TRASTUZUMAB",200.640 EUR.,33690000,Del 01/11/2024,"ABBVIE SPAIN, S.L.U.",B86418787,200.640 EUR,according to the technical report,200640.0
23/S/19/SU/DG/A/AM008,14-06-2019,General Directorate of Economic Resources of the Canarian Health Service,,http://www.gobiernodecanarias.org/sanidad,,,,"Supply of the active ingredients Adalimumab, Trastuzumab and Rituximab to the Canary Islands Health Service","55.418.461,08 EUR.",33690000,2 Year(s),,,,,55418461.08
2019/026161,04-02-2020,Management of the Guadalajara Integrated Care Area,Autonomous Community,http://contratacion.castillalamancha.es/,949209212,949209245,eserrano@sescam.org,PNSP 10/2019 Acquisition of the active ingredients Palivizumab and Adalimumab (Abbvie Spain SLU)-61034000GU19SUM00009,"518.713,79 EUR.",33600000,24 Month(s),"ABBVIE FARMACEUTICA, S.L.U.",B86418787,"518.713,79 EUR",Awarded to the offer with the best quality-price ratio,518713.79
906/2024HCD,13-11-2024,General Defense Health Inspection,State authority,,914222936,914222936,contratacion.igesan@mde.es,ta2025 supply of hyrimoz adalimumab biosimilar - hcd l1 derived from a.m. 2021/064 ingesa (01-01-2025 until 12-15-2025),"86.538,46 EUR.",33690000,Del 31/10/2024,SANDOZ FARMACEUTICA S.A.,A08233801,"86.538,46 EUR",contract based on a framework agreement,86538.46
907/2024HCD,13-12-2024,General Defense Health Inspection,State authority,,914222936,914222936,contratacion.igesan@mde.es,ta2025 supply of imraldi adalimumab biosimilar - hcd l1 derived from a.m. 2021/064 ingesa (01-01-2025 until 12-15-2025),"67.307,69 EUR.",33600000,Del 06/11/2024,"BIOGEN SPAIN, SL",B83086736,"67.307,69 EUR",contract based on a framework agreement,67307.69
HV BASADO AM 2021/064 A08130502,04-05-2023,Cantabrian Health Service,Autonomous Community,http://www.scsalud.es,+34 942202769,+34 942202639,contratacion.dg@scsalud.es,In,"22.078,8 EUR.","33100000, 33140000",Del 03/05/2023,"Fresenius Medical Care España, S.A.",A08130502,"22.078,8 EUR",Bidder with the best offer in relation to quality and price in the opinion of the contracting body LCSP 9/2017,22078.8
SSCC PD 62/25,13-03-2025,Health Service of the Balearic Islands,Regional authority,http://www.ibsalut.es,+034 971175600,,departamentocontratacion@ibsalut.es,Supply of biosimilars derived from AM 2021/64 lot 1Adalimumab,"480.733,2 EUR.",33600000,,Sandoz Farmaceutica,A08233801,"480.733,2 EUR",resolution,480733.2
SSCC PD 137/25,10-06-2025,Health Service of the Balearic Islands,Regional authority,http://www.ibsalut.es,+034 971175600,,departamentocontratacion@ibsalut.es,Supply of biosimilars derived from AM 2021/64 lot 1Adalimumab,"1.294.353,6 EUR.",33600000,8 Month(s),Sandoz Farmaceutica,A08233801,"1.294.353,6 EUR",approval and award resolution,1294353.6
SS CC PD 18/23,12-06-2023,Health Service of the Balearic Islands,Autonomous Community,http://www.ibsalut.es,,,departamentocontratacion@ibsalut.es,Supply of similar biological medications derived from AM 2021/64 Lot 1 – Adalimumab,2.278.944 EUR.,"33000000, 33600000",Del 02/02/2023,"Sandoz Farmacéutica, S.A",A08233801,2.278.944 EUR,resolution,2278944.0
SS CC PD 333/24,16-12-2024,Health Service of the Balearic Islands,Regional authority,http://www.ibsalut.es,+034 971175600,,departamentocontratacion@ibsalut.es,Supply of biosimilars derived from AM 2021/64 lot 1,478.470 EUR.,33600000,Del 01/01/2025,Sandoz Farmaceutica,A08233801,478.470 EUR,resolution,478470.0
2022/001112,14-03-2022,Tomelloso Integrated Care Management,Autonomous Community,http://contratacion.castillalamancha.es/,926525800,926525874,ptorress@sescam.jccm.es,Supply of subcutaneous Adalimumab for Tomelloso GAI (Lot 90 of AM 2019/000150),83.750 EUR.,33600000,24 Month(s),"HELP CHABILY, S.A.U.",A08130502,83.750 EUR,Based contract. Most advantageous offer,83750.0
2022/001215,21-03-2022,Management of the Manzanares Integrated Care Area,Autonomous Community,http://contratacion.castillalamancha.es/,926646036,926646035,contratacion_gaim@sescam.jccm.es,Acquisition of subcutaneous ADALIMUMAB for 24 months derived from SESCAM Framework Agreement 2019/000150,167.500 EUR.,33600000,24 Month(s),"HELP CHABILY, S.A.U.",A08130502,167.500 EUR,"Best offer, according to AM",167500.0
2022/001514,01-04-2022,Integrated Care Management of Ciudad Real,Autonomous Community,http://contratacion.castillalamancha.es/,926278000,926278536,contratacion_hgucr@sescam.jccm.es,LOT 90 Acquisition of subcutaneous ADALIMUMAB for the Integrated Care Management of Ciudad Real.,996.558 EUR.,33600000,24 Month(s),"HELP CHABILY, S.A.U.",A08130502,498.279 EUR,best value for money,996558.0
2022/001765,13-04-2022,Albacete Integrated Care Management,Autonomous Community,http://contratacion.castillalamancha.es/,967597212,967243952,suministros.contratacion@sescam.jccm.es,Lot 90 Framework Agreement for medicines 2019/000150 (Adalimumab),797.702 EUR.,33600000,24 Month(s),"HELP CHABILY, S.A.U.",A08130502,398.851 EUR,Best value for money,797702.0
2022/001943,30-03-2022,Management of the Valdepeñas Integrated Care Area,Autonomous Community,http://contratacion.castillalamancha.es/,926320200,926310159,contratacion.hgor@sescam.jccm.es,Supply of subcutaneous Adalimumab for the Valdepeñas Integrated Care Management (Lot 90 of A.M. 2019/000150),268.000 EUR.,33600000,24 Month(s),"HELP CHABILY, S.A.U.",A08130502,134.000 EUR,Best offer,268000.0
2022/002408,29-04-2022,Hellín Integrated Care Area Management,Autonomous Community,http://contratacion.castillalamancha.es/,967309542,967305019,contratacion.gaihellin@sescam.jccm.es,"LOT 90 subcutaneous ADALIMUMAB: Contract Based on A. M. 2019/000150 medications, serums and contrasts for GAI of Hellín.",167.500 EUR.,33600000,24 Month(s),"HELP CHABILY, S.A.U.",A08130502,83.750 EUR,As established in the A.M. 2019/000150.,167500.0
2022/003283,12-05-2022,Talavera de la Reina Integrated Care Management,Autonomous Community,http://contratacion.castillalamancha.es/,925803600,925822219,jgvalverde@sescam.jccm.es,Lot 90 1- Subcutaneous Adalimumab,351.080 EUR.,,24 Month(s),"HELP CHABILY, S.A.U.",A08130502,351.080 EUR,Most advantageous offer,351080.0
2022/003283,12-05-2022,Talavera de la Reina Integrated Care Management,Autonomous Community,http://contratacion.castillalamancha.es/,925803600,925822219,jgvalverde@sescam.jccm.es,Lot 90 2- Subcutaneous Adalimumab,16.600 EUR.,,24 Month(s),SANDOZ FARMACEUTICA S.A,A08233801,16.600 EUR,most advantageous offer,16600.0
2022/003624,11-04-2022,Management of the Guadalajara Integrated Care Area,Autonomous Community,http://contratacion.castillalamancha.es/,949209212,949209245,contratacion.guadalajara@sescam.jccm.es,"Acquisition ""Subcutaneous Adalimumab"" (lot 90) for 24 months based on Framework Agreement 2019/000150",670.000 EUR.,33600000,24 Month(s),"HELP CHABILY, S.A.U.",A08130502,670.000 EUR,"Best offer, according to Framework Agreement",670000.0
23/S/23/SU/DG/A/AM15,05-01-2024,General Directorate of Economic Resources of the Canarian Health Service,,http://www3.gobiernodecanarias.org/sanidad/scs/,,,,"Supply of medicines containing the active ingredients adalimumab (20, 40 and 80 mg), rituximab (100 and 500 mg) and trastuzumab (150 and 420 mg), destined for the Canary Islands Health Service",45.401.804 EUR.,33690000,2 Year(s),,,,,45401804.0
23/S/23/SU/DG/A/AM15,05-01-2024,General Directorate of Economic Resources of the Canarian Health Service,,http://www3.gobiernodecanarias.org/sanidad/scs/,,,,"Supply of medicines containing the active ingredients adalimumab (20, 40 and 80 mg), rituximab (100 and 500 mg) and trastuzumab (150 and 420 mg), destined for the Canary Islands Health Service",45.401.804 EUR.,33690000,2 Year(s),,,,,45401804.0
2023/001084,20-03-2023,Villarrobledo Integrated Care Management,Autonomous Community,http://contratacion.castillalamancha.es/,967133018,967133016,contratacion.gaivil@sescam.jccm.es,adalimumab subcutaneous-1,"165.992,5 EUR.",,,"HELP CHABILY, S.A.U.",A08130502,"68.842,5 EUR",According to Maarco Agreement,165992.5
2023/001084,20-03-2023,Villarrobledo Integrated Care Management,Autonomous Community,http://contratacion.castillalamancha.es/,967133018,967133016,contratacion.gaivil@sescam.jccm.es,adalimumab subcutaneous-2,"91.661,22 EUR.",,,"MYLAN PHARMACEUTICALS, S.L.",B62735675,"38.025,72 EUR",According to Framework Agreement,91661.22
2023/001116,17-05-2023,Almansa Integrated Care Management,Autonomous Community,http://contratacion.castillalamancha.es/,967339536,967339549,contratacion.hgalmansa@sescam.jccm.es,Supply of Medicines derived from AM SESCAM: lot 90 subcutaneous ADALIMUMAB,473.472 EUR.,33600000,24 Month(s),"MYLAN PHARMACEUTICALS, S.L.",B62735675,236.736 EUR,"Best offer, being the first of the successful bidders that does not have sodium citrate as an excipient",473472.0
2023/001263,15-03-2023,Integrated Care Management of Ciudad Real,Autonomous Community,http://contratacion.castillalamancha.es/,926278000,926278536,contratacion_hgucr@sescam.jccm.es,lot 90 Acquisition of subcutaneous ADALIMUMAB for the Integrated Care Management of Ciudad Real,617.271 EUR.,33600000,12 Month(s),Sandoz Farmaceutica,A08233801,"308.635,5 EUR",Awardee AM,617271.0
2023/001561,23-03-2023,Puertollano Integrated Care Management,Autonomous Community,http://perfilcontratante.jccm.es/picos,926421100,926422334,contratacion_pllano@sescam.jccm.es,Contract based Lot 90 Adalimumab,498.000 EUR.,33600000,24 Month(s),Sandoz Farmaceutica,A08233801,249.000 EUR,according to Framework Agreement,498000.0
2023/001745,17-03-2023,Management of the Valdepeñas Integrated Care Area,Autonomous Community,http://contratacion.castillalamancha.es/,926320200,926310159,contratacion.hgor@sescam.jccm.es,Supply of subcutaneous Adalimumab for the Valdepeñas Integrated Care Management (Lot 90 A.M. 2019/000150),46.314 EUR.,33600000,12 Month(s),Sandoz Farmaceutica,A08233801,15.438 EUR,Most advantageous offer,46314.0
2023/001896,16-03-2023,Talavera de la Reina Integrated Care Management,Autonomous Community,http://contratacion.castillalamancha.es/,925803600,925822219,jgvalverde@sescam.jccm.es,Contract Based A.M. 2019/000150 Lot 90 Subcutaneous Adalimumab,181.604 EUR.,33600000,14 Month(s),Sandoz Farmaceutica,A08233801,181.604 EUR,Most advantageous offer,181604.0
2023/006009,12-06-2023,Cuenca Integrated Care Management,Autonomous Community,http://contratacion.castillalamancha.es/,969179912,969224900,contrataciongaicuenca@sescam.jccm.es,"Sum med., sera and contrasts Lot 90 Adalimumab","424.005,5 EUR.",33690000,11 Month(s),Sandoz Farmaceutica,A08233801,"133.256,5 EUR",Framework Agreement Execution,424005.5
CB/2023/007/GCE,14-12-2023,Health Care Management of the National Institute of Health Management in Ceuta,State authority,https://contrataciondelestado.es/wps/portal/plataforma,856907000,856907065,sersum.ae.ceuta@ingesa.sanidad.gob.es,Supply of Adalimumab to the Pharmacy Service of the University Hospital of Ceuta.,258.300 EUR.,33600000,24 Month(s),Sandoz Farmaceutica,A08233801,172.200 EUR,Clinical and logistical criteria.,258300.0
2023/008270,28-07-2023,Integrated Care Management of Ciudad Real,Regional authority,http://contratacion.castillalamancha.es/,926278000,926278536,contratacion_hgucr@sescam.jccm.es,Lot 90 Acquisition of subcutaneous Adalimumab for the Integrated Care Management of Ciudad Real,543.600 EUR.,33600000,10 Month(s),BIOGEN SPAIN S.L.,B83086736,271.800 EUR,According to Framework Agreement 2019/000150,543600.0
2023/008271,14-07-2023,Cuenca Integrated Care Management,Regional authority,http://contratacion.castillalamancha.es/,969179912,969224900,contrataciongaicuenca@sescam.jccm.es,"Sum med., sera and contrasts Lot 90 Adalimumab",14.800 EUR.,33690000,9 Month(s),"AMGEN,S.A.",A59363655,4.000 EUR,by reasoned resolution,14800.0
2023/011509,18-09-2023,Integrated Care Management of Alcázar de San Juan,Regional authority,http://contratacion.castillalamancha.es/,926580522,926551166,contratacion.gaiaj@sescam.jccm.es,Medicines batch 90 subcutaneous adalimumab,281.400 EUR.,33600000,24 Month(s),"HELP CHABILY, S.A.U.",A08130502,140.700 EUR,according to frame,281400.0
2024/000834,10-04-2024,Talavera de la Reina Integrated Care Management,Regional authority,http://contratacion.castillalamancha.es/,925803600,925822219,jgvalverde@sescam.jccm.es,Lot 90 subcutaneous adalimumab (Based on extension AM 2019/000150),4.218.592 EUR.,33600000,24 Month(s),"HELP CHABILY, S.A.U.",A08130502,682.060 EUR,Most advantageous economic offer,4218592.0
2024/011062,01-12-2024,General Secretary of the Health Service of Castilla-La Mancha,,http://contratacion.castillalamancha.es/,,,,Framework Agreement for the Selection of Suppliers of Biological Medicines for Centers Dependent on SESCAM,"137.090.493,96 EUR.",33600000,2 Year(s),,,,,137090493.96
2025/005523,26-05-2025,Tomelloso Integrated Care Management,Regional authority,http://contratacion.castillalamancha.es/,926525800,926525874,ptorress@sescam.jccm.es,Adalimumab lote 1 AM 2024/011062,8.000 EUR.,33600000,24 Month(s),"AMGEN,S.A.",A59363655,4.000 EUR,based contract,8000.0
2025/005610,30-07-2025,Cuenca Integrated Care Management,Regional authority,http://contratacion.castillalamancha.es/,969179912,969224900,contrataciongaicuenca@sescam.jccm.es,Biological Medicines Lot 1 Adalimumab 20 mg injectable,2.080 EUR.,33600000,24 Month(s),"AMGEN,S.A.",A59363655,2.080 EUR,"The awarding of supply contracts based on the framework agreement will comply with the procedure established in clause AE.2.B) of Annex I of the Specific Administrative Clauses of the Framework Agreement, without the need to call the parties to a new tender.",2080.0
2025/005679,09-06-2025,Tomelloso Integrated Care Management,Regional authority,http://contratacion.castillalamancha.es/,926525800,926525874,ptorress@sescam.jccm.es,Adalimumab 80 mg inyectable,46.000 EUR.,33600000,24 Month(s),Sandoz Farmaceutica,A08233801,23.000 EUR,contract based on framework agreement 2024/00162 lot 2,46000.0
2025/006237,17-06-2025,Integrated Care Management of Ciudad Real,Regional authority,http://contratacion.castillalamancha.es/,926278000,926278536,contratacion_hgucr@sescam.jccm.es,Lot 1 Acquisition of Adalimumab 20 mg injectable for the Integrated Care Management of Ciudad Real,1.760 EUR.,33600000,24 Month(s),"AMGEN,S.A.",A59363655,880 EUR,Most advantageous offer according to AM 2024/011062,1760.0
2025/006408,26-06-2025,Management of the Guadalajara Integrated Care Area,Regional authority,http://contratacion.castillalamancha.es/,949209212,949209245,contratacion.guadalajara@sescam.jccm.es,"Acquisition of ADALIMUMAB 20 MG INJECTABLE for the G.A.I. from Guadalajara. Contract based on A.M. 2024/011062 (Lot 1), for the selection of suppliers of biological medicines for centers dependent on SESCAM.",19.200 EUR.,33600000,24 Month(s),"AMGEN,S.A.",A59363655,9.600 EUR,"The award is made to the offer with the best quality-price ratio, in accordance with the provisions of the PCAP and PPT.",19200.0
2025/006413,25-06-2025,Management of the Guadalajara Integrated Care Area,Regional authority,http://contratacion.castillalamancha.es/,949209212,949209245,contratacion.guadalajara@sescam.jccm.es,"Acquisition of ADALIMUMAB 80 MG INJECTABLE for the G.A.I. from Guadalajara. Contract based on A.M. 2024/011062 (Lot 2), for the selection of suppliers of biological medicines for centers dependent on SESCAM.",207.000 EUR.,33600000,24 Month(s),Sandoz Farmaceutica,A08233801,103.500 EUR,"The award is made to the offer with the best quality-price ratio, in accordance with the provisions of the PCAP and PPT.",207000.0
2025/006468,22-07-2025,Cuenca Integrated Care Management,Regional authority,http://contratacion.castillalamancha.es/,969179912,969224900,contrataciongaicuenca@sescam.jccm.es,Biological medications L2 Injectable Adalimumab,16.560 EUR.,33600000,24 Month(s),Sandoz Farmaceutica,A08233801,16.560 EUR,"In accordance with the provisions of article 117 of the LCSP, once the contracting file is completed, a reasoned resolution will be issued by the contracting body approving it. Said resolution will also imply the approval of the expense",16560.0
2025/006728,25-07-2025,Puertollano Integrated Care Management,Regional authority,http://perfilcontratante.jccm.es/picos,926421100,926422334,contratacion_pllano@sescam.jccm.es,Contract Based Lot 1 ADALIMUMAB 20 injectable,2.400 EUR.,33600000,24 Month(s),"AMGEN,S.A.",A59363655,1.200 EUR,According to Framework Agreement.,2400.0
2025/007171,17-07-2025,Albacete Integrated Care Management,Regional authority,http://contratacion.castillalamancha.es/,967597212,967243952,suministros.contratacion@sescam.jccm.es,Lot 1 CD Biological medications Adalimumab 20 mg injectable,26.400 EUR.,33600000,24 Month(s),"AMGEN,S.A.",A59363655,13.200 EUR,most advantageous economic offer,26400.0
2025/007172,22-07-2025,Albacete Integrated Care Management,Regional authority,http://contratacion.castillalamancha.es/,967597212,967243952,suministros.contratacion@sescam.jccm.es,Lot 2 CD Biological Medications Lot 2 Adalimumab 80 mg injectable,419.980 EUR.,33600000,24 Month(s),Sandoz Farmaceutica,A08233801,209.990 EUR,most advantageous economic offer,419980.0
2025/007747,24-07-2025,Villarrobledo Integrated Care Management,Regional authority,http://contratacion.castillalamancha.es/,967133018,967133016,contratacion.gaivil@sescam.jccm.es,Scientists 80 AM 2024/011022,85.100 EUR.,33600000,24 Month(s),Sandoz Farmaceutica,A08233801,42.550 EUR,Best value for money,85100.0
2025/008194,06-08-2025,Integrated Care Management of Alcázar de San Juan,Regional authority,http://contratacion.castillalamancha.es/,926580522,926551166,contratacion.gaiaj@sescam.jccm.es,biological drugs lot 2 injectable adalimumab,34.500 EUR.,33600000,24 Month(s),Sandoz Farmaceutica,A08233801,34.500 EUR,according to frame,34500.0
2025/010027,02-09-2025,Management of the Manzanares Integrated Care Area,Regional authority,http://contratacion.castillalamancha.es/,926646036,,contratacion.hva@sescam.jccm.es,Scientists 2024/011062 lote 02 Surprised 80 angusable,57.500 EUR.,33600000,718 Day(s),Sandoz Farmaceutica,A08233801,28.750 EUR,Best value for money offer,57500.0
CS/01/C000001553/23/PNSP,30-10-2023,Badajoz Health Area Management,Regional authority,http://www.areasaludbadajoz.com,+34 924218174,+34 924248054,juanluis.gonzalez@salud-juntaex.es,Drug supply ADALIMUMAB drug HUMIRA 40 mg prec pen 0.4 ml,"559.597,5 EUR.",33600000,12 Month(s),"ABBVIE SPAIN, S.L.U.",B86418787,"559.597,5 EUR",Negotiated without advertising for exclusivity,559597.5
53/F/24/SU/GE/T/0024-1,18-06-2024,Fuerteventura Health Service Management,Regional authority,http://www3.gobiernodecanarias.org/sanidad/scs/,+34 928862027,+34 928862009,contratahgf.scs@gobiernodecanarias.org,"Rituximab 100 y 500 mg, C2 y C1","10.871,34 EUR.",,,"ROCHE FARMA, S.A.",A08023145,"10.871,34 EUR","Awardee of the Framework Agreement, file: 23/S/19SU/DG/A/AM8",10871.34
23/S/23/SU/DG/A/AM15-01 - Lote 2 - Abbvie,28-06-2024,Management Directorate of the Insular Maternal and Child University Hospital Complex,Regional authority,https://www3.gobiernodecanarias.org/sanidad/scs,+928 444149,+928 444182,gerenchuimiscs@gobiernodecanarias.org,Riteximab (100 and 500 Mg) and Trastuzumab (20 and 420 Mg). Canaria.,45.144 EUR.,33690000,21 Month(s),"ABBVIE SPAIN, S.L.U.",B86418787,45.144 EUR,"By resolution 799/2024, of May 10, of the General Directorate of Economic Resources of the Canary Islands Health Service, by which file 23/S/23/SU/DG/A/AM15 was awarded for the Supply of the active ingredients Adalimumab (20, 40 and 80 mg), Rituximab (100 and 500 mg) and Trastuzumab (150 and 420 mg) destined for the Canary Islands Health Service, through a framework agreement.",45144.0
51/F/23/SU/GE/D/0329,10-10-2024,Address Management University Hospital of Gran Canaria Doctor Negrín,Regional authority,http://www.gobiernodecanarias.org/sanidad/scs,+034 928450147,+034 928449814,ucahugcdn.scs@gobiernodecanarias.org,"Contract based on the framework agreement for the supply of the active ingredients ADALIMUMAB, RITUXIMAB and TRASTUZUMAB","25.117,5 EUR.",33690000,Del 18/10/2024,"SANOFI AVENTIS, S.A.",A08163586,"25.117,5 EUR",according to the technical report,25117.5
53/F/23/SU/GE/T/0080-1,21-09-2023,Fuerteventura Health Service Management,Regional authority,http://www3.gobiernodecanarias.org/sanidad/scs/,+34 928862027,+34 928862009,contratahgf.scs@gobiernodecanarias.org,Rituximab 100 mg. C/2 Y 500 mg C/1,"7.933,14 EUR.",,,"ROCHE FARMA, S.A.",A08023145,"7.933,14 EUR",Awarddee of the Framework Agreement File: 23/S/19/SU/DG/A/Am0,7933.14
CS/9999/1101097086/AM/2023,14-07-2023,Murcian Health Service - Purchasing Board,,,,,,"Supply of Medications with active ingredients Adalimumab, etanercept and apoetin alfa for subcutaneous administration","60.910.911,6 EUR.",33652000,12 Month(s),,,,,60910911.6
52/F/25/SU/GE/T/001-03_ LOTE 1,26-03-2025,Health Services Management of the Lanzarote Health Area,Regional authority,http://www.gobiernodecanarias.org,+34 928478909,+34 928815034,contratacionpublica-hdjmo.scs@gobiernodecanarias.org,"Supply of medicines containing the active ingredients Adalimumab (20, 40 and 80 mg), Rituximab (100 and 500 mg) and Trastuzumab (150 and 420 mg) within the scope of the Canary Islands Health Service, destined for the Doctor José Molina Orosa University Hospital, through accession to Framework Agreement No. 23/S/23/SU/DG/A/AM15, open procedure and ordinary processing","6.520,8 EUR.",33690000,12 Month(s),"ABBVIE SPAIN, S.L.U.",B86418787,"6.520,8 EUR","By Resolution number 933, dated March 25, 2025, of the Health Services Management of the Health Area of ​​Lanzarote.",6520.8
23/S/23/SU/DG/A/AM15-01 - Lot 1 - Abbvie,28-06-2024,Management Directorate of the Insular Maternal and Child University Hospital Complex,Regional authority,https://www3.gobiernodecanarias.org/sanidad/scs,+928 444149,+928 444182,gerenchuimiscs@gobiernodecanarias.org,Riteximab (100 and 500 Mg) and Trastuzumab (20 and 420 Mg). Canaria.,30.096 EUR.,33690000,21 Month(s),"ABBVIE SPAIN, S.L.U.",B86418787,30.096 EUR,"By resolution 799/2024, of May 10, of the General Directorate of Economic Resources of the Canary Islands Health Service, by which file 23/S/23/SU/DG/A/AM15 was awarded for the Supply of the active ingredients Adalimumab (20, 40 and 80 mg), Rituximab (100 and 500 mg) and Trastuzumab (150 and 420 mg) destined for the Canary Islands Health Service, through a framework agreement.",30096.0
CS/01/C000001350/21/PNSP,31-05-2021,Badajoz Health Area Management,Autonomous Community,http://www.areasaludbadajoz.com,+34 924218174,+34 924248054,juanluis.gonzalez@salud-juntaex.es,Exclusive supplies of the medication Adalimumab (Humira) 40 mg prec pen 0.4 ml destined for hospital pharmacies in the Badajoz Health Area.,"560.208,83 EUR.",33600000,9 Month(s),"Abbvie Spain, S.L.U.",B86418787,"560.208,83 EUR",Negotiated procedure for exclusivity.,560208.83
51/F/24/SU/GE/D/0306,10-10-2024,Address Management University Hospital of Gran Canaria Doctor Negrín,Regional authority,http://www.gobiernodecanarias.org/sanidad/scs,+034 928450147,+034 928449814,ucahugcdn.scs@gobiernodecanarias.org,"Contract based on the framework agreement for the supply of the active ingredients ADALIMUMAB, RITUXIMAB and TRASTUZUMAB",48.300 EUR.,33690000,Del 15/10/2024,PFIZERSLU,B28089225,48.300 EUR,according to the technical report,48300.0
SAS_BAR_2025_DAM_39 (LOT 1),25-03-2025,Barbastro Health Sector Management,Regional authority,,+34 974249032,,sum.hbrb@salud.aragon.es,"Supply of original biological and biosimilar medicines based on the active ingredient ADALIMUMAB 20 mg for the Barbastro Hospital (Derived from the Homologation Framework Agreement 62 DG/20, Lot 1)",1.248 EUR.,"33000000, 33600000",Del 01/04/2025,"ABBVIE SPAIN, S.L.U.",B86418787,"940,5 EUR",The offer meets the specific needs for the Barbastro Hospital,1248.0
53/F/24/SU/GE/T/0095,17-10-2024,Fuerteventura Health Service Management,Regional authority,http://www3.gobiernodecanarias.org/sanidad/scs/,+34 928862027,+34 928862009,contratahgf.scs@gobiernodecanarias.org,"Adalimumab 20 MG 0,4 ML C/2",627 EUR.,,,"ABBVIE SPAIN, S.L.U.",B86418787,627 EUR,"Awardee of the Framework Agreement, file: 23/S/23/SU/DG/A/AM15",627.0
53/F/24/SU/GE/T/0095,17-10-2024,Fuerteventura Health Service Management,Regional authority,http://www3.gobiernodecanarias.org/sanidad/scs/,+34 928862027,+34 928862009,contratahgf.scs@gobiernodecanarias.org,Adalimumab 80 mg C/1 PEN,87.780 EUR.,,,KERN PHARMA S.L.,B58296773,88.407 EUR,"Awardee of the Framework Agreement, file: 23/S/23/SU/DG/A/AM15",88407.0
53/F/24/SU/GE/T/0095,17-10-2024,Fuerteventura Health Service Management,Regional authority,http://www3.gobiernodecanarias.org/sanidad/scs/,+34 928862027,+34 928862009,contratahgf.scs@gobiernodecanarias.org,Adalimumab 80 mg C/1 PEN,5.400 EUR.,,,KERN PHARMA S.L.,B58296773,5.400 EUR,"Awardee of the Framework Agreement, file: 23/S/23/SU/DG/A/AM15",5400.0
53/F/21/SU/GE/T/0043,16-11-2021,Fuerteventura Health Service Management,Autonomous Community,http://www3.gobiernodecanarias.org/sanidad/scs/,+34 928862027,+34 928862009,contratahgf.scs@gobiernodecanarias.org,Rituximab 100 y 500 mg,,,,"ROCHE FARMA, S.A.",A08023145,"33.105,6 EUR","Awarddee of the Framework Agreement, File: 23/S/20/SU/DG/A/Am0",33105.6
52/F/25/SU/GE/T/001-03_LOTE 3,31-03-2025,Health Services Management of the Lanzarote Health Area,Regional authority,http://www.gobiernodecanarias.org,+34 928478909,+34 928815034,contratacionpublica-hdjmo.scs@gobiernodecanarias.org,"Supply of medicines containing the active ingredients Adalimumab (20, 40 and 80 mg), Rituximab (100 and 500 mg) and Trastuzumab (150 and 420 mg) within the scope of the Canary Islands Health Service, destined for the Doctor José Molina Orosa University Hospital, through accession to Framework Agreement No. 23/S/23/SU/DG/A/AM15, open procedure and ordinary processing",222.200 EUR.,33690000,12 Month(s),"KERN PHARMA, S.L.",B58296773,222.200 EUR,"By Resolution number 933, dated March 25, 2025, of the Health Services Management of the Health Area of ​​Lanzarote.",222200.0
53/F/24/SU/GE/T/0113,16-12-2024,Fuerteventura Health Service Management,Regional authority,http://www3.gobiernodecanarias.org/sanidad/scs/,+34 928862027,+34 928862009,contratahgf.scs@gobiernodecanarias.org,Adalimumab 40 mg - Vial/Prefilled Syringe/Pen,12.900 EUR.,,,KERN PHARMA S.L.,B58296773,12.900 EUR,"Awardee of the Framework Agreement, file: 23/S/23/SU/DG/A/AM15",12900.0
53/F/24/SU/GE/T/0113,16-12-2024,Fuerteventura Health Service Management,Regional authority,http://www3.gobiernodecanarias.org/sanidad/scs/,+34 928862027,+34 928862009,contratahgf.scs@gobiernodecanarias.org,Adalimumab 80 mg C/1 Pen,27.000 EUR.,,,KERN PHARMA S.L.,B58296773,27.000 EUR,"Awardee of the Framework Agreement, file: 23/S/23/SU/DG/A/AM15",27000.0
52/F/25/SU/GE/T/001-03_ LOTE 4,26-03-2025,Health Services Management of the Lanzarote Health Area,Regional authority,http://www.gobiernodecanarias.org,+34 928478909,+34 928815034,contratacionpublica-hdjmo.scs@gobiernodecanarias.org,"Supply of medicines containing the active ingredients Adalimumab (20, 40 and 80 mg), Rituximab (100 and 500 mg) and Trastuzumab (150 and 420 mg) within the scope of the Canarian Health Service, destined for the Doctor José Molina Orosa University Hospital, through accession to Framework Agreement No. 23/S/23/SU/DG/A/AM15, open procedure and processing ordinary.",40.080 EUR.,33690000,12 Month(s),PFIZERSLU,B28089225,40.080 EUR,"By Resolution number 933, dated March 25, 2025, of the Health Services Management of the Health Area of ​​Lanzarote.",40080.0
51/F/23/SU/GE/D/0107,27-03-2023,Address Management University Hospital of Gran Canaria Doctor Negrín,Autonomous Community,http://www.gobiernodecanarias.org/sanidad/scs,+034 928450147,+034 928449814,ucahugcdn.scs@gobiernodecanarias.org,"Contract based on the framework agreement for the supply of drugs adalimumab, trastuzumab and rituximab",564.300 EUR.,33690000,Del 29/03/2023,"ABBVIE SPAIN, S.L.U.",B86418787,564.300 EUR,according to the technical report,564300.0
53/F/23/SU/GE/T/0080,21-09-2023,Fuerteventura Health Service Management,Regional authority,http://www3.gobiernodecanarias.org/sanidad/scs/,+34 928862027,+34 928862009,contratahgf.scs@gobiernodecanarias.org,Adalimumab 40 mg,376.200 EUR.,,,"ABBVIE SPAIN, S.L.",B86418787,376.200 EUR,"Awarddee of the Framework Agreement, File: 23/S/19/SU/DG/A/Am0",376200.0
53/F/23/SU/GE/T/0080,21-09-2023,Fuerteventura Health Service Management,Regional authority,http://www3.gobiernodecanarias.org/sanidad/scs/,+34 928862027,+34 928862009,contratahgf.scs@gobiernodecanarias.org,Trastuzumab 150 mg C/1,"17.470,6 EUR.",,,PFIZER S.L.U.,B84118694,"17.470,6 EUR","Awarddee of the Framework Agreement, File: 23/S/19/SU/DG/A/Am0",17470.6
53/F/23/SU/GE/T/0080,21-09-2023,Fuerteventura Health Service Management,Regional authority,http://www3.gobiernodecanarias.org/sanidad/scs/,+34 928862027,+34 928862009,contratahgf.scs@gobiernodecanarias.org,Rituximab 100 mg. C/2 y 500mg. C/1,"28.354,4 EUR.",,,KERN PHARMA S.L.,B58296773,"28.354,4 EUR","Awarddee of the Framework Agreement, File: 23/S/19/SU/DG/A/Am0",28354.4
SAS_BAR_2025_DAM_39 (LOT 2),25-03-2025,Barbastro Health Sector Management,Regional authority,,+34 974249032,,sum.hbrb@salud.aragon.es,"Supply of original biological and biosimilar medicines based on the active ingredient ADALIMUMAB 40 mg for the Barbastro Hospital (Derived from the Homologation Framework Agreement 62 DG/20, Lot 2)",147.472 EUR.,"33000000, 33600000",Del 01/04/2025,"ABBVIE SPAIN, S.L.U.",B86418787,18.810 EUR,The offer meets the specific needs for the Barbastro Hospital,147472.0
51/F/22/SU/GE/D/0134,02-03-2022,Address Management University Hospital of Gran Canaria Doctor Negrín,Autonomous Community,http://www.gobiernodecanarias.org/sanidad/scs,+034 928450147,+034 928449814,ucahugcdn.scs@gobiernodecanarias.org,"Contract based on the framework agreement for the supply of the active ingredients adalimumab, trasstuzumab and rituximab",395.010 EUR.,33690000,Del 02/03/2022,"ABBVIE SPAIN, S.L.U.",B86418787,395.010 EUR,according to the technical report,395010.0
51/F/22/SU/GE/D/0135-5,17-02-2022,Address Management University Hospital of Gran Canaria Doctor Negrín,Autonomous Community,http://www.gobiernodecanarias.org/sanidad/scs,+034 928450147,+034 928449814,ucahugcdn.scs@gobiernodecanarias.org,"contract based on the framework agreement for the supply of the active ingredients adalimumab, trastuzumab and rituximab",376.200 EUR.,33690000,Del 17/02/2022,Sandoz Farmaceutica,A08233801,376.200 EUR,according to pharmacy request,376200.0
55/F/21/SU/GE/T/223,17-11-2021,Managing Director of the Nuestra Señora de Candelaria University Hospital,Autonomous Community,http://www3.gobiernodecanarias.org/sanidad/scs/,+034 922601800,+034 922602129,cadmhunsc.scs@gobiernodecanarias.org,"Supply of the active ingredients Adalimumab, Trastuzumab and Rituximab, derived from the Framework Agreement, for the Pharmacy Service of the Ntra. Sra. de Candelaria University Hospital","5.365.262,7 EUR.",33690000,Del 01/01/2022,"ABBVIE SPAIN, S.L.U.",B86418787,1.640.520 EUR,Framework Agreement Award.,5365262.7
CS/99/1124045146/24/PNSP,28-01-2025,General Directorate of Economic Planning,Regional authority,,+34 924382500,+34 924382754,ses.sgeca@salud-juntaex.es,"Contract based on the Framework Agreement for the supply of the drug HUMIRA® (ADALIMUMAB) for the continuation of current treatments, excluding new treatments, destined for the pharmacies of the hospitals of the Extremadura Health Service.","7.678.492,8 EUR.",33690000,12 Month(s),"ABBVIE SPAIN, S.L.U.",B86418787,1.785.696 EUR,Best value for money,7678492.8
56/F/24/SU/GE/D/081 3,28-08-2024,Management of Health Services of the La Palma Health Area,Regional authority,http://www.gobiernodecanarias.org,+34 922185151,+34 922185151,contra-hglp.scs@gobiernodecanarias.org,Adalimumab 40 MG,2.088 EUR.,,,"Sandoz Farmacéutica, SA",A08233801,2.088 EUR,Bidder awarded the framework agreement.,2088.0
23/S/19/SU/DG/A/AM008,14-06-2019,General Directorate of Economic Resources of the Canarian Health Service,,http://www.gobiernodecanarias.org/sanidad,,,,"Supply of the active ingredients Adalimumab, Trastuzumab and Rituximab to the Canary Islands Health Service","55.418.461,08 EUR.",33690000,2 Year(s),,,,,55418461.08
51/F/24/SU/GE/D/0304,25-11-2024,Address Management University Hospital of Gran Canaria Doctor Negrín,Regional authority,http://www.gobiernodecanarias.org/sanidad/scs,+034 928450147,+034 928449814,ucahugcdn.scs@gobiernodecanarias.org,"Contract based on a framework agreement for the supply of the active ingredients ADALIMUMAB, RITUXIMAB and TRASTUZUMAB",154.800 EUR.,33690000,Del 28/11/2024,"KERN PHARMA, S.L.",B58296773,154.800 EUR,According to technical advice report,154800.0
52/F/25/SU/GE/T/001-03_ LOTE 5,31-03-2025,Health Services Management of the Lanzarote Health Area,Regional authority,http://www.gobiernodecanarias.org,+34 928478909,+34 928815034,contratacionpublica-hdjmo.scs@gobiernodecanarias.org,"Supply of medicines containing the active ingredients Adalimumab (20, 40 and 80 mg), Rituximab (100 and 500 mg) and Trastuzumab (150 and 420 mg) within the scope of the Canarian Health Service, destined for the Doctor José Molina Orosa University Hospital, through accession to Framework Agreement No. 23/S/23/SU/DG/A/AM15, open procedure and ordinary processing",40.080 EUR.,33690000,12 Month(s),PFIZERSLU,B28089225,40.080 EUR,"By Resolution number 933, dated March 25, 2025, of the Health Services Management of the Health Area of ​​Lanzarote.",40080.0
51/F/23/SU/GE/D/0108,17-03-2023,Address Management University Hospital of Gran Canaria Doctor Negrín,Autonomous Community,http://www.gobiernodecanarias.org/sanidad/scs,+034 928450147,+034 928449814,ucahugcdn.scs@gobiernodecanarias.org,"Contract based on the framework agreement for the supply of drugs adalimumab, trastuzumab and rituximab",67.200 EUR.,33690000,Del 20/03/2023,BIOGEN SPAIN S.L.,B83086736,67.200 EUR,according to the technical report,67200.0
51/F/24/SU/GE/D/0302,21-10-2024,Address Management University Hospital of Gran Canaria Doctor Negrín,Regional authority,http://www.gobiernodecanarias.org/sanidad/scs,+034 928450147,+034 928449814,ucahugcdn.scs@gobiernodecanarias.org,"Supply of the active ingredients adalimumab, rituximab and trastuzumab",870.000 EUR.,33690000,Del 01/02/2023,Sandoz Farmaceutica,A08233801,870.000 EUR,According to the Pharmacy Service Report,870000.0
PC 134 HMS/2021,26-08-2021,Health Sector Management of Zaragoza 2,Autonomous Community,,,,concursos-hms@salud.aragon.es,"Supply of biological and biosimilar medicines based on the active ingredients Adalimumab, Trastuzumaz, Etanercept, Rituximab, Infliximab and Bevacizumab for the Miguel Servet University Hospital in Zaragoza","11.038.850,05 EUR.",33600000,12 Month(s),"ABBVIE SPAIN, S.L.U.",B86418787,"1.918.630,77 EUR",Award of contracts derived from the Framework Agreement 62 DG/20,11038850.05
53/F/22/SU/GE/T/0023,06-04-2022,Fuerteventura Health Service Management,Autonomous Community,http://www3.gobiernodecanarias.org/sanidad/scs/,+34 928862027,+34 928862009,contratahgf.scs@gobiernodecanarias.org,Adalimumab 40 mg,,,,"ABBVIE SPAIN, S.L.U.",B86418787,564.300 EUR,Awarddee of Framework Agreement 23/S/19/SU/DG/A/Am0,564300.0
53/F/22/SU/GE/T/0023,06-04-2022,Fuerteventura Health Service Management,Autonomous Community,http://www3.gobiernodecanarias.org/sanidad/scs/,+34 928862027,+34 928862009,contratahgf.scs@gobiernodecanarias.org,Rituximab,,,,"ROCHE FARMA, S.A.",A08023145,29.382 EUR,Awarddee of Framework Agreement 23/S/19/SU/DG/A/Am0,29382.0
23/S/23/SU/DG/A/AM15-01 - Lot 2 - Sandoz,28-06-2024,Management Directorate of the Insular Maternal and Child University Hospital Complex,Regional authority,https://www3.gobiernodecanarias.org/sanidad/scs,+928 444149,+928 444182,gerenchuimiscs@gobiernodecanarias.org,Riteximab (100 and 500 Mg) and Trastuzumab (20 and 420 Mg). Canaria.,1.733.040 EUR.,33690000,21 Month(s),Sandoz Farmaceutica,A08233801,1.733.040 EUR,"By resolution 799/2024, of May 10, of the General Directorate of Economic Resources of the Canary Islands Health Service, by which file 23/S/23/SU/DG/A/AM15 was awarded for the Supply of the active ingredients Adalimumab (20, 40 and 80 mg), Rituximab (100 and 500 mg) and Trastuzumab (150 and 420 mg) destined for the Canary Islands Health Service, through a framework agreement.",1733040.0
55/F/24/SU/GE/T/0009,07-08-2024,Managing Director of the Nuestra Señora de Candelaria University Hospital,Regional authority,http://www3.gobiernodecanarias.org/sanidad/scs/,+034 922601800,+034 922602129,cadmhunsc.scs@gobiernodecanarias.org,"Supply of the active ingredients Adalimumab (20,40,80 mg), Rituximab (100 and 500 mg.) and Trastuzumab (150 and 420 mg), contract based on Framework Agreement 23/S/23/SU/DG/A/AM15.","9.778.739,2 EUR.",33690000,Del 01/09/2024,"ABBVIE SPAIN, S.L.U.",B86418787,"254.311,2 EUR",Best Offer,9778739.2
23/S/23/SU/DG/A/AM15-01 - Lote 4 - Sandoz,28-06-2024,Management Directorate of the Insular Maternal and Child University Hospital Complex,Regional authority,https://www3.gobiernodecanarias.org/sanidad/scs,+928 444149,+928 444182,gerenchuimiscs@gobiernodecanarias.org,Riteximab (100 and 500 Mg) and Trastuzumab (20 and 420 Mg). Canaria.,347.724 EUR.,33690000,21 Month(s),Sandoz Farmaceutica,A08233801,347.724 EUR,"By resolution 799/2024, of May 10, of the General Directorate of Economic Resources of the Canary Islands Health Service, by which file 23/S/23/SU/DG/A/AM15 was awarded for the Supply of the active ingredients Adalimumab (20, 40 and 80 mg), Rituximab (100 and 500 mg) and Trastuzumab (150 and 420 mg) destined for the Canary Islands Health Service, through a framework agreement.",347724.0
51/F/22/SU/GE/D/0137,08-03-2022,Address Management University Hospital of Gran Canaria Doctor Negrín,Autonomous Community,http://www.gobiernodecanarias.org/sanidad/scs,+034 928450147,+034 928449814,ucahugcdn.scs@gobiernodecanarias.org,"Contract based on the framework agreement for the supply of the active ingredients adalimumab, trastuzumab and rituximab",100.800 EUR.,33690000,Del 09/03/2022,BIOGEN SPAIN S.L.,B83086736,100.800 EUR,according to the technical report,100800.0
56/F/24/SU/GE/D/081 1,28-08-2024,Management of Health Services of the La Palma Health Area,Regional authority,http://www.gobiernodecanarias.org,+34 922185151,+34 922185151,contra-hglp.scs@gobiernodecanarias.org,Adalimumab 20 MG,7.524 EUR.,,,"Abbvie Spain, SLU",B86418787,7.524 EUR,Bidder awarded the framework agreement.,7524.0
56/F/24/SU/GE/D/081 1,28-08-2024,Management of Health Services of the La Palma Health Area,Regional authority,http://www.gobiernodecanarias.org,+34 922185151,+34 922185151,contra-hglp.scs@gobiernodecanarias.org,Adalimumab 40 MG,"24.076,8 EUR.",,,"Abbvie Spain, SLU",B86418787,"24.076,8 EUR",Bidder awarded the framework agreement.,24076.8
53/F/23/SU/GE/T/0028,11-09-2023,Fuerteventura Health Service Management,Regional authority,http://www3.gobiernodecanarias.org/sanidad/scs/,+34 928862027,+34 928862009,contratahgf.scs@gobiernodecanarias.org,Adalimumab 40 mg,225.720 EUR.,,,"ABBVIE SPAIN, S.L.",B86418787,225.720 EUR,"Awarddee Framework Agreement, File: 23/S/19/SU/DG/A/Am0",225720.0
53/F/23/SU/GE/T/0028,11-09-2023,Fuerteventura Health Service Management,Regional authority,http://www3.gobiernodecanarias.org/sanidad/scs/,+34 928862027,+34 928862009,contratahgf.scs@gobiernodecanarias.org,Trastuzumab 150mg,"13.726,9 EUR.",,,PFIZER GEP S.L.U.,B84118694,"13.726,9 EUR","Awarddee Framework Agreement, File: 23/S/19/SU/DG/A/Am0",13726.9
53/F/23/SU/GE/T/0028,11-09-2023,Fuerteventura Health Service Management,Regional authority,http://www3.gobiernodecanarias.org/sanidad/scs/,+34 928862027,+34 928862009,contratahgf.scs@gobiernodecanarias.org,Rituximab 100 y 500 mg,"32.163,2 EUR.",,,KERN PHARMA S.L.,B58296773,"32.163,2 EUR","Awarddee Framework Agreement, File: 23/S/19/SU/DG/A/Am0",32163.2
56/F/24/SU/GE/D/081 2,28-08-2024,Management of Health Services of the La Palma Health Area,Regional authority,http://www.gobiernodecanarias.org,+34 922185151,+34 922185151,contra-hglp.scs@gobiernodecanarias.org,Adalimumab 40 MG,156.520 EUR.,,,"Kern Pharma, SL",B58296773,156.520 EUR,Bidder awarded the framework agreement.,156520.0
56/F/24/SU/GE/D/081 2,28-08-2024,Management of Health Services of the La Palma Health Area,Regional authority,http://www.gobiernodecanarias.org,+34 922185151,+34 922185151,contra-hglp.scs@gobiernodecanarias.org,Adalimumab 80 MG,78.000 EUR.,,,"Kern Pharma, SL",B58296773,78.000 EUR,Bidder awarded the framework agreement.,78000.0
56/F/24/SU/GE/D/081 2,28-08-2024,Management of Health Services of the La Palma Health Area,Regional authority,http://www.gobiernodecanarias.org,+34 922185151,+34 922185151,contra-hglp.scs@gobiernodecanarias.org,Rituximab 500 MG,87.000 EUR.,,,"Kern Pharma, SL",B58296773,87.000 EUR,Bidder awarded the framework agreement.,87000.0
56/F/24/SU/GE/D/081 2,28-08-2024,Management of Health Services of the La Palma Health Area,Regional authority,http://www.gobiernodecanarias.org,+34 922185151,+34 922185151,contra-hglp.scs@gobiernodecanarias.org,Trastuzumab 420 MG,16.632 EUR.,,,"Kern Pharma, SL",B58296773,16.632 EUR,Bidder awarded the framework agreement.,16632.0
23/S/23/SU/DG/A/AM15-01 - Lote 5 - Pfizer,28-06-2024,Management Directorate of the Insular Maternal and Child University Hospital Complex,Regional authority,https://www3.gobiernodecanarias.org/sanidad/scs,+928 444149,+928 444182,gerenchuimiscs@gobiernodecanarias.org,Riteximab (100 and 500 Mg) and Trastuzumab (20 and 420 Mg). Canaria.,169.344 EUR.,33690000,21 Month(s),PFIZERSLU,B28089225,169.344 EUR,"By resolution 799/2024, of May 10, of the General Directorate of Economic Resources of the Canary Islands Health Service, by which file 23/S/23/SU/DG/A/AM15 was awarded for the Supply of the active ingredients Adalimumab (20, 40 and 80 mg), Rituximab (100 and 500 mg) and Trastuzumab (150 and 420 mg) destined for the Canary Islands Health Service, through a framework agreement.",169344.0
53/F/21/SU/GE/N/0032,20-05-2021,Fuerteventura Health Service Management,Autonomous Community,http://www3.gobiernodecanarias.org/sanidad/scs/,+34 928862027,+34 928862009,contratahgf.scs@gobiernodecanarias.org,Pharmaceutical supply of the active ingredient Adalimumab 80 mg for the Health Services Management of the Fuerteventura Health Area.,165.528 EUR.,33690000,12 Month(s),"ABBVIE SPAIN, S.L.U.",B86418787,75.240 EUR,"As established in the Award Resolution of the Health Services Management of the Fuerteventura Health Area No. 1269/2021 dated May 16, 2021, by which the contracting file number 53/F/21/SU/GE/N/0032 is awarded, for the pharmaceutical supply of the active ingredient Adalimumab 80 mg, for this Management.",165528.0
23/S/23/SU/DG/A/AM15,05-01-2024,General Directorate of Economic Resources of the Canarian Health Service,,http://www3.gobiernodecanarias.org/sanidad/scs/,,,,"Supply of medicines containing the active ingredients adalimumab (20, 40 and 80 mg), rituximab (100 and 500 mg) and trastuzumab (150 and 420 mg), destined for the Canary Islands Health Service",45.401.804 EUR.,33690000,2 Year(s),,,,,45401804.0
51/F/22/SU/GE/D/0135,17-02-2022,Address Management University Hospital of Gran Canaria Doctor Negrín,Autonomous Community,http://www.gobiernodecanarias.org/sanidad/scs,+034 928450147,+034 928449814,ucahugcdn.scs@gobiernodecanarias.org,"contract based on the framework agreement for the supply of the active ingredients adalimumab, trastuzumab and rituximab",711.000 EUR.,"33000000, 33690000",Del 17/02/2022,Sandoz Farmaceutica,A08233801,711.000 EUR,according to the request of the pharmacy service,711000.0
52/F/21/SU/GE/T/048,17-05-2021,Health Services Management of the Lanzarote Health Area,Autonomous Community,http://www.gobiernodecanarias.org,+34 928595392,+34 928815034,uchgl.scs@gobiernodecanarias.org,"Adalimumab (Humira 40MG/0,4 ml J.Prec. E/2 ( 709242) y (Humira 40MG/0,4 ml Plu.Prec. E/2 (CN 709452)",,"709242, 709452",,"ABBVIE SPAIN, S.L.U.",B86418787,100.800 EUR,"Award Resolution number 552 of March 15, 2021 of the Health Services Management of the Health Area of ​​Lanzarote",100800.0
52/F/21/SU/GE/T/048,17-05-2021,Health Services Management of the Lanzarote Health Area,Autonomous Community,http://www.gobiernodecanarias.org,+34 928595392,+34 928815034,uchgl.scs@gobiernodecanarias.org,Trastuzumab (Trazimera 150 MG 1 vial powder infusion) CN 723755,,723755,,"PFIZER, S.L.U.",B28089225,99.832 EUR,"Award Resolution number 552 of March 15, 2021 of the Health Services Management of the Health Area of ​​Lanzarote",99832.0
52/F/21/SU/GE/T/048,17-05-2021,Health Services Management of the Lanzarote Health Area,Autonomous Community,http://www.gobiernodecanarias.org,+34 928595392,+34 928815034,uchgl.scs@gobiernodecanarias.org,Rituximab (Truxima 100 MG vial 10ML E/2) CN 718649 y (Truxima 500 MG vial 50ML E/1) CN 715592,,"718649, 715592",,"KERN PHARMA, S.L.",B58296773,68.770 EUR,"Award Resolution number 552 of March 15, 2021 of the Health Services Management of the Health Area of ​​Lanzarote",68770.0
CS/99/1124045146/24/AM,03-12-2024,General Directorate of Economic Planning,Regional authority,,+34 924382500,+34 924382754,ses.sgeca@salud-juntaex.es,"Framework Agreement for the Supply of the drug Humira (Adalimumab) to the pharmacies of the hospitals of the Extremadura Health Service, following the Negotiated Procedure without Advertising provided for in article 168 A) 2 of Law 9/2017.","31.482.365,29 EUR.",33690000,12 Month(s),"ABBVIE SPAIN, S.L.U.",B86418787,1.785.696 EUR,Best value for money,31482365.29
52/F/25/SU/GE/T/001-03_ LOTE 2,31-03-2025,Health Services Management of the Lanzarote Health Area,Regional authority,http://www.gobiernodecanarias.org,+34 928478909,+34 928815034,contratacionpublica-hdjmo.scs@gobiernodecanarias.org,"Supply of medicines containing the active ingredients Adalimumab (20, 40 and 80 mg), Rituximab (100 and 500 mg) and Trastuzumab (150 and 420 mg) within the scope of the Canary Islands Health Service, destined for the Doctor José Molina Orosa University Hospital, through accession to Framework Agreement No. 23/S/23/SU/DG/A/AM15, open procedure and ordinary processing",222.200 EUR.,33690000,12 Month(s),"KERN PHARMA, S.L.",B58296773,222.200 EUR,"By Resolution number 933, dated March 25, 2025, of the Health Services Management of the Health Area of ​​Lanzarote.",222200.0
53/F/24/SU/GE/T/0024,18-06-2024,Fuerteventura Health Service Management,Regional authority,http://www3.gobiernodecanarias.org/sanidad/scs/,+34 928862027,+34 928862009,contratahgf.scs@gobiernodecanarias.org,Adalimumab 40 mg,"311.493,6 EUR.",,,"ABBVIE SPAIN, S.L.",B86418787,"311.493,6 EUR","Awarddee of the Framework Agreement, File: 23/S/19/SU/DG/N/Am8",311493.6
53/F/24/SU/GE/T/0024,18-06-2024,Fuerteventura Health Service Management,Regional authority,http://www3.gobiernodecanarias.org/sanidad/scs/,+34 928862027,+34 928862009,contratahgf.scs@gobiernodecanarias.org,Rituximab,13.225 EUR.,,,KERN PHARMA S.L.,B58296773,13.225 EUR,"Awarddee of the Framework Agreement, File: 23/S/19/SU/DG/N/Am8",13225.0
53/F/25/SU/GE/T/0017,07-05-2025,Fuerteventura Health Service Management,Regional authority,http://www3.gobiernodecanarias.org/sanidad/scs/,+34 928862027,+34 928862009,contratahgf.scs@gobiernodecanarias.org,Adalimumab 40 mg - Vial / Prefilled Syringe / Pen,141.556 EUR.,,,KERN PHARMA S.L.,B58296773,141.556 EUR,"Awardee of the Framework Agreement, file: 23/S/23/SU/DG/A/AM15.",141556.0
53/F/25/SU/GE/T/0017,07-05-2025,Fuerteventura Health Service Management,Regional authority,http://www3.gobiernodecanarias.org/sanidad/scs/,+34 928862027,+34 928862009,contratahgf.scs@gobiernodecanarias.org,Adalimumab 80 mg - Vial/Prefilled Syringe/Pen,108.000 EUR.,,,KERN PHARMA S.L.,B58296773,108.000 EUR,"Awardee of the Framework Agreement, file: 23/S/23/SU/DG/A/AM15.",108000.0
53/F/25/SU/GE/T/0017,07-05-2025,Fuerteventura Health Service Management,Regional authority,http://www3.gobiernodecanarias.org/sanidad/scs/,+34 928862027,+34 928862009,contratahgf.scs@gobiernodecanarias.org,Rituximab 100 y 500 mg,14.732 EUR.,,,KERN PHARMA S.L.,B58296773,14.732 EUR,"Awardee of the Framework Agreement, file: 23/S/23/SU/DG/A/AM15.",14732.0
53/F/25/SU/GE/T/0017,07-05-2025,Fuerteventura Health Service Management,Regional authority,http://www3.gobiernodecanarias.org/sanidad/scs/,+34 928862027,+34 928862009,contratahgf.scs@gobiernodecanarias.org,Trastuzumab 150 Trazimer,4.200 EUR.,,,PFIZER S.L.U.,B28089225,4.200 EUR,"Awardee of the Framework Agreement, file: 23/S/23/SU/DG/A/AM15.",4200.0
